Skip to main content
. 2020 Nov 13;45(1):265–277. doi: 10.3892/or.2020.7852

Figure 2.

Figure 2.

CASC9 promotes BC cell proliferation. (A) The relative expression levels of CASC9 in BC cell lines (T24, TCCSUP, UM-UC-3, J82 and 5637) compared with normal human bladder epithelial cells (SV-HUC-1). (B) The efficacy of CASC9 siRNAs. (C and D) The proliferation rate of 5637 and J82 cells transfected with 50 nM siCASC9-1, siCASC9-3 or siNC measured by EdU assay. Scale bars, 100 µm. (E) The proliferation rate of 5637 and J82 cells transfected with 50 nM siCASC9-1, siCASC9-3 or siNC measured by CKK-8 assay reported as the means ± SEM from 3 independently repeated experiments. (F and G) The apoptotic rate of siCASC9- and siNC-transfected cells (P>0.05). Unpaired Student's t-test was used and data are presented as the mean ± SEM. *P<0.05, **P<0.01 and ****P<0.0001. CASC9, cancer susceptibility candidate 9; BC, bladder cancer; siRNAs, small interfering RNAs; NC, negative control; EdU, 5-ethynyl-2′-deoxyuridine; CCK-8, Cell Counting Kit-8; SEM, standard error of mean.